|
|
 |
|
Viewing report
|
|
|
|
Pharmaceutical Pricing and Reimbursement: Strategies for Market Access Across the US, Europe, Japan and Other Key Geographies
Business Insights, Nov 2007, Pages: 143
The global pharmaceutical pricing and reimbursement environment is notoriously complex and continuously changing. Pharma companies must implement strategic pricing assessments across global markets and product lifecycle phases in order to develop effective pricing policies. By incorporating such assessments into portfolio evaluations and lifecycle planning, companies can enhance their understanding of potential price profiles for individual drugs and optimise future returns. ‘Pharmaceutical Pricing and Reimbursement’ is a new report published by Business Insights that examines the tactical importance of price optimization throughout the product lifecycle. The key issues affecting pricing and reimbursement disciplines are identified and the market environments of individual countries are assessed. This report will also detail the global and lifecycle pricing strategies of new and established drugs, including actionable recommendations and detailed case studies, and provide forecasts for future pricing scenarios in major markets.
Top five reasons to order your copy today
-Anticipate shifts in the global pricing environment with this report’s unique forecasts of the best-case, worst case and most likely pricing scenarios for major countries.
-Improve your price optimization strategies by assessing the impacts of pharmacoeconomic evaluations, parallel trade and reimportation, and generic substitution across key countries.
-Co-ordinate your reimbursement policies more effectively across global markets by evaluating the latest pricing developments in the markets of Japan, France, Germany, Italy, Spain, Canada, Australia, China, the US and the UK.
-Develop optimal global pricing strategies throughout the lifecycles of your leading drugs by examining key considerations during the phases of launch, patent protection and patent expiry.
-Benchmark the pricing tactics of leading companies with this report’s range of successful case studies for a variety of drugs and pricing environments.
Key issues examined in this report...
-Medicare Part D. Doubts have been raised over whether the wider access and coverage associated with Part D drug benefits will outweigh the potential increases in negotiating power for centralized government agencies.
-US re-importation. The re-importation of drugs from Canada to the US has caused friction amongst states, creating a divide between those who support drug availability in online pharmacies and those who oppose such measures. An eventual legislative resolution is unlikely to support bulk re-importation.
-EU accession. Although the accession of 10 new countries has lowered EU reference prices and increased the future potential of parallel imports and generic competition, inward importation from accession countries is likely to protect the EU-15 from major impact.
-Global target pricing. International reference pricing and parallel trade have led to calls for launching key drugs with a common international price. However, optimizing launch sequences with varying prices remains the current strategy of preference.
Your questions answered...
-What are the most influential issues currently affecting pricing and reimbursement policies?
-How will the pricing environments of major pharma markets develop over the next five years?
-Will the benefits of enhanced drug accessibility overcome safety and quality concerns in the debate over Canadian re-importations?
-How will widened EU membership continue to influence reference prices, parallel imports and generic competition in the EU-15?
-To what extent will the introduction of Medicare Part D reforms affect drug prices for seniors in the US?
-How can the application of global pricing strategies help to maximize returns throughout each phase of the product lifecycle?
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Pharmaceutical Pricing Strategies: Price optimization, reimbursement and regulation in Europe, US and Japan
Pharmaceutical Pricing, Reimbursement and Parallel Trade 2006
Pharmaceutical Pricing and Reimbursement in the United Kingdom, 2008
Strategic Overview of Pharmaceutical Pricing and Reimbursement in the Major Markets
Pricing & Reimbursement - Seven Major Markets Update
Pharmaceutical Pricing and Reimbursement in France, 2008
Pharmaceutical Pricing and Reimbursement in China
Orphan Drugs in Europe: Pricing, Reimbursement, Funding and Market Access Issues
Pharmaceutical Pricing and Reimbursement in Italy, 2008
Pharmaceutical Pricing, Reimbursement, and Prescribing News in the First Quarter of 2007
Special Report: Pharmaceutical Pricing and Reimbursement in Germany, 2008
Pricing and Reimbursement Risk and Opportunities in Pharmaceutical Deal Making
|
|
|
|
